open access

Online first
Short communication
Published online: 2023-02-05
Get Citation

A favorable alliance between repetitive use of levosimendan and advanced heart failure: Polish two-centered inpatient perspective in need of validation

Marcin Książczyk1, Marcin Gruchała2, Iwona Stopczyńska2, Małgorzata Lelonek1
DOI: 10.33963/KP.a2023.0034
Pubmed: 36739649
  1. Department of Noninvasive Cardiology, Medical University of Lodz, Łódź, Poland
  2. 1st Department of Cardiology, Medical University of Gdansk, Gdańsk, Poland

open access

Online first
Short communication
Published online: 2023-02-05


Not available


Not available
Get Citation
Supp./Additional Files (1)
Supplementary material
About this article

A favorable alliance between repetitive use of levosimendan and advanced heart failure: Polish two-centered inpatient perspective in need of validation


Kardiologia Polska (Polish Heart Journal)


Online first

Article type

Short communication

Published online


Page views


Article views/downloads







Marcin Książczyk
Marcin Gruchała
Iwona Stopczyńska
Małgorzata Lelonek

References (15)
  1. Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20(11): 1505–1535.
  2. McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42: 3599–3726.
  3. Lelonek M, Stopczyńska I, Korościk E, et al. Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure. Adv Clin Exp Med. 2020; 29(11): 1305–1312.
  4. Ahmad T, Miller PE, McCullough M, et al. Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. Eur J Heart Fail. 2019; 21(9): 1064–1078.
  5. Tycińska A, Gierlotka M, Bugajski J, et al. Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society. Kardiol Pol. 2020; 78(7-8): 825–834.
  6. Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013; 1(2): 103–111.
  7. Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002; 360(9328): 196–202.
  8. Levy B, Buzon J, Kimmoun A. Inotropes and vasopressors use in cardiogenic shock: when, which and how much? Curr Opin Crit Care. 2019; 25(4): 384–390.
  9. Belletti A, Castro ML, Silvetti S, et al. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br J Anaesth. 2015; 115(5): 656–675.
  10. Delaney A, Bradford C, McCaffrey J, et al. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. Int J Cardiol. 2010; 138(3): 281–289.
  11. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007; 297(17): 1883–1891.
  12. Comín-Colet J, Manito N, Segovia-Cubero J, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018; 20(7): 1128–1136.
  13. García-González MJ, de Mora-Martín M, López-Fernández S, et al. Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study. Cardiovasc Drugs Ther. 2013; 27(6): 573–579.
  14. Altenberger J, Parissis JT, Costard-Jaeckle A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail. 2014; 16(8): 898–906.
  15. Tycińska A, Gierlotka M, Bartuś S, et al. Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. Adv Med Sci. 2022; 67(1): 18–22.


Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: